Pulse.

a daily field guide to health research that matters

◆ Console

‹ Sun · 8 Nov 2026
Standard addition

Impact of venetoclax-based therapies on CLL-associated autoimmune cytopenias: A retrospective study conducted by ERIC.

Venetoclax-based therapy shows promise for managing autoimmune blood cell deficiencies that sometimes occur with chronic lymphocytic leukemia.

This PubMed-indexed study examined impact of venetoclax-based therapies on cll-associated autoimmune cytopenias: a retrospective study conducted by eric. Hemasphere 2026 Nov 6;10(11):e70522.

What the study was

Study design
Retrospective multicenter cohort study
Population
Human participants or human evidence described in the PubMed abstract
Sample size
1720
Category
Treatment Innovation
Maturity
Validated
Journal
HemaSphere

Why it surfaced

Retrospective multicenter cohort study with PubMed abstract evidence; scored conservatively for treatment innovation relevance and evidence maturity.

A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.